Cardiovascular Devices are used in treating diseases related to the heart and the circulatory system. Structural Heart Occlusion Devices are used to close defects in heart, reducing the risk of stroke and treating congenital heart defects. GlobalData uses proprietary data and analytics to provide a comprehensive report on the structural heart occlusion devices devices market, including market shares of different players within Belgium. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the structural heart occlusion devices market in Belgium was Abbott Laboratories followed by W. L. Gore & Associates, Boston Scientific, AtriCure, Occlutech, pfm medical and LifeTech Scientific.
Structural Heart Occlusion Devices provide minimally invasive treatment options for the closure of congenital heart defects and for stroke risk reduction. The closure interventions are typically performed through a transcatheter approach, which eliminates the need for open heart surgery, enabling faster recovery times. The structural heart occlusion device consists of Atrial Septal Defect Occluders, Ventricular Septal Defect Occluders, Patent Ductus Arteriosus Closure Devices, Patent Foramen Ovale Closure Devices and Left Atrial Appendage Closure Devices.
The value of the structural heart occlusion devices devices market within Belgium was expected to be over $10m in 2023.
For the latest complete market share analysis of structural heart occlusion devices device market in Belgium, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.